The Effects of Montelukast on Intradermal Wheal and Flare

Hill, Samuel L.; Krouse, John H.

doi:10.1016/s0194-5998(03)00607-7

Cited by 19 publications

(7 citation statements)

References 23 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly the case for oral H 1 -antihistamines, but also for other drugs which are not necessarily used for the treatment of allergic diseases (for review see Refs 1149, 1229, 1230; Table 13). Montelukast does not appear to reduce skin test reactivity (1231,1232) and does not need to be discontinued before skin testing. Patients with skin disease may not be tested because of dermographism (urticaria) or widespread skin lesions.…”

Section: Skin Testsmentioning

confidence: 98%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,801

1,761

View full text Add to dashboard Cite

Section: Skin Testsmentioning

confidence: 98%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,801

1,761

View full text Add to dashboard Cite

“…This is particularly the case for oral H 1 -antihistamines. Montelukast neither appears to reduce skin test reactivity 289 290 nor needs to be discontinued before skin testing.…”

Section: Diagnosismentioning

confidence: 99%

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis

Cheng

Chen

et al. 2018

Allergy Asthma Immunol Res

240

198

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a global health problem that causes major illnesses and disabilities worldwide. Epidemiologic studies have demonstrated that the prevalence of AR has increased progressively over the last few decades in more developed countries and currently affects up to 40% of the population worldwide. Likewise, a rising trend of AR has also been observed over the last 2–3 decades in developing countries including China, with the prevalence of AR varying widely in these countries. A survey of self-reported AR over a 6-year period in the general Chinese adult population reported that the standardized prevalence of adult AR increased from 11.1% in 2005 to 17.6% in 2011. An increasing number of original articles and imporclinical trials on the epidemiology, pathophysiologic mechanisms, diagnosis, management and comorbidities of AR in Chinese subjects have been published in international peer-reviewed journals over the past 2 decades, and substantially added to our understanding of this disease as a global problem. Although guidelines for the diagnosis and treatment of AR in Chinese subjects have also been published, they have not been translated into English and therefore not generally accessible for reference to non-Chinese speaking international medical communities. Moreover, methods for the diagnosis and treatment of AR in China have not been standardized entirely and some patients are still treated according to regional preferences. Thus, the present guidelines have been developed by the Chinese Society of Allergy to be accessible to both national and international medical communities involved in the management of AR patients. These guidelines have been prepared in line with existing international guidelines to provide evidence-based recommendations for the diagnosis and management of AR in China.

show abstract

“…Montelukast does not modify skin prick test results (117, 118) and therefore does not need to be discontinued before skin testing.…”

mentioning

confidence: 99%

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN)

Bousquet

Cauwenberge

Khaled

et al. 2006

Allergy

127

View full text Add to dashboard Cite

The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence‐based and step‐wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti‐IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non‐nasal symptoms are presented as these will be discussed in a separate document.

show abstract

The Effects of Montelukast on Intradermal Wheal and Flare

Abstract: Montelukast does not need to be discontinued before intradermal allergy testing.

Cited by 19 publications

References 23 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN)

Contact Info

Product

Resources

About

The Effects of Montelukast on Intradermal Wheal and Flare

Abstract: Montelukast does not need to be discontinued before intradermal allergy testing.

Cited by 19 publications

References 23 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

Contact Info

Product

Resources

About

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN)